Form 8-K · Current Report · Filed 2026-09-01
Moderna Announces Private Placement of $3 Billion Convertible Senior Notes
Moderna, Inc. has completed a private offering of $3,000,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032. The notes are convertible into shares of Moderna's common stock under certain conditions and are subject to various events of default. The company intends to use the net proceeds for general corporate purposes, including potential investments in its oncology business and repayment of debt. Additionally, Moderna entered into capped call transactions to reduce potential dilution upon conversion of the notes.
- Filer
- Moderna Inc. MRNA · NASDAQ
- Filed
- Accession
- 0001193125-26-378505
- CIK
- 0001682852
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$140.34
Since filing
+0.0%
Latest close
$140.34
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from MRNA reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, MRNA insiders reported 28 Form 4 transactions — net selling of $14.6M.
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Never miss another MRNA filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.